Stifel: AtkinsRealis Poised to Outperform Peers

Stifel's Analysis on AtkinsRealis

A Stifel report highlights that AtkinsRealis shares have gained 0.4% year-to-date, contrasting with declines from competitors Stantec and WSP Global. The firm trades at a premium valuation, with an 18.5 times price-to-earnings multiple for 2027.

This performance gap underscores investor confidence in the company's strategic positioning despite broader market pressures affecting its peers.

Performance and Forecasts

Stifel's Q1 2026 adjusted EBITDA estimate for AtkinsRealis is $225 million, which is 6% below the market consensus of $238 million. However, their full-year 2026 projection of $1.184 billion aligns closely with expectations, suggesting a stronger performance anticipated later in the year.

Key Risks and Opportunities

The primary near-term risk involves a potential temporary weakness in the company's Nuclear backlog. This is expected to persist until new contract awards materialize in the second half of 2026. Despite this, Stifel views the stock's strong Nuclear business outlook and underleveraged balance sheet as significant long-term opportunities.

Investment Outlook

Stifel suggests that despite the premium valuation and potential for short-term volatility, any price weakness could represent a compelling buying opportunity. The firm remains positive on the company's fundamental strengths, particularly within its high-demand nuclear division.

FAQ

Q: Why is AtkinsRealis outperforming its competitors this year?
A: AtkinsRealis stock has gained 0.4% year-to-date, while competitors like Stantec and WSP Global have seen significant double-digit declines.

Q: What is the main risk for AtkinsRealis according to Stifel?
A: Stifel warns of a potential temporary slowdown in its Nuclear backlog until new contracts are secured in the second half of 2026.

Source: Investing.com